MedTrace Logo

Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.

NCT00324766 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2012-06-26

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of a 24 hour infusion with levosimendan in patients with acute myocardial infarction and heart failure after acute percutaneous coronary intervention (PCI) treatment.

Conditions

Interventions

DRUG

levosimendan

1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min

DRUG

placebo,

24 h, infusion

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Trygve Husebye, MD, · Department of Cardiology, Ulleval University Hospital

  • Geir Ø Andersen, MD, PhD · Department of Cardiology, Ulleval University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2011-09-30
Completion
2012-03-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00324766 on ClinicalTrials.gov